SHAPETX Trademark

Trademark Overview

On Friday, December 18, 2020, a trademark application was filed for SHAPETX with the United States Patent and Trademark Office. The USPTO has given the SHAPETX trademark a serial number of 90394153. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, April 8, 2024. This trademark is owned by Shape Therapeutics, Inc.. The SHAPETX trademark is filed in the Medical & Beauty Services & Agricultural Services category with the following description:

provision of gene therapy services for medical treatment purposes
shapetx

General Information

Serial Number90394153
Word MarkSHAPETX
Filing DateFriday, December 18, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, April 8, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing5000 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, July 13, 2021

Trademark Statements

Description of MarkThe mark consists of the word "SHAPE" with initial capital letter "S" followed by the smaller capital letters "TX" appearing as a superscript.
Pseudo MarkSHAPE TX
Goods and Servicesprovision of gene therapy services for medical treatment purposes

Classification Information

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, March 2, 2021
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameShape Therapeutics Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSeattle, WA 98109
Party NameShape Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSeattle, WA 98109

Trademark Events

Event DateEvent Description
Monday, April 8, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, April 8, 2024ABANDONMENT - NO USE STATEMENT FILED
Saturday, August 12, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 10, 2023SOU EXTENSION 4 GRANTED
Thursday, August 10, 2023SOU EXTENSION 4 FILED
Thursday, August 10, 2023SOU TEAS EXTENSION RECEIVED
Thursday, July 6, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, July 6, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, July 6, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Saturday, February 11, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 9, 2023SOU EXTENSION 3 GRANTED
Thursday, February 9, 2023SOU EXTENSION 3 FILED
Thursday, February 9, 2023SOU TEAS EXTENSION RECEIVED
Saturday, September 3, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 1, 2022SOU EXTENSION 2 GRANTED
Thursday, September 1, 2022SOU EXTENSION 2 FILED
Thursday, September 1, 2022SOU TEAS EXTENSION RECEIVED
Friday, March 11, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 10, 2022SOU EXTENSION 1 GRANTED
Wednesday, February 23, 2022SOU EXTENSION 1 FILED
Thursday, March 10, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, March 3, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, February 23, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, September 7, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, August 25, 2021CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Wednesday, August 25, 2021ASSIGNED TO PETITION STAFF
Thursday, August 19, 2021TEAS POST PUBLICATION AMENDMENT RECEIVED
Tuesday, July 13, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 13, 2021PUBLISHED FOR OPPOSITION
Wednesday, June 23, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, June 7, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, June 7, 2021ASSIGNED TO EXAMINER
Tuesday, March 2, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, December 22, 2020NEW APPLICATION ENTERED

Related Keywords

shapetx treatment purposes medical services gene therapy provision